Merck KGaA (FRA:MRK) has been assigned a €112.00 ($131.76) target price by investment analysts at equinet AG in a research report issued on Friday. The brokerage presently has a “buy” rating on the healthcare company’s stock. equinet AG’s price objective would indicate a potential upside of 20.94% from the company’s previous close.

MRK has been the subject of a number of other reports. J P Morgan Chase & Co set a €100.00 ($117.65) price target on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Friday, October 6th. Citigroup Inc. set a €123.00 ($144.71) price target on shares of Merck KGaA and gave the company a “buy” rating in a research report on Monday, September 25th. Goldman Sachs Group, Inc. (The) set a €105.00 ($123.53) price target on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Tuesday, September 19th. Kepler Capital Markets set a €119.00 ($140.00) price target on shares of Merck KGaA and gave the company a “buy” rating in a research report on Thursday, September 21st. Finally, DZ Bank AG restated a “sell” rating on shares of Merck KGaA in a research report on Tuesday, July 18th. Thirteen equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of €109.17 ($128.44).

Merck KGaA (FRA:MRK) traded down €0.24 ($0.28) during trading on Friday, reaching €92.61 ($108.95). 407,761 shares of the company were exchanged. Merck KGaA has a fifty-two week low of €89.00 ($104.71) and a fifty-two week high of €115.00 ($135.29).

ILLEGAL ACTIVITY NOTICE: “Merck KGaA (MRK) Given a €112.00 Price Target by equinet AG Analysts” was reported by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/11/05/merck-kgaa-mrk-given-a-112-00-price-target-by-equinet-ag-analysts.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.